v9302 Search Results


v 9302  (MedChemExpress)
94
MedChemExpress v 9302
V 9302, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v9302/V-9302/10__3390_slash_cancers18071068-131-23-24
Average 94 stars, based on 1 article reviews
v 9302 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
v-9302 hydrochloride  (MuseChem Chemicals)
N/A
V-9302 hydrochloride(CAT: L004733) bearing a unique identifier, plays a pivotal role in pharmaceutical and organic chemistry. Its specific structure suggests its potential as a modulator of specific cellular pathways or targets. In pharmaceutical research, it
   Buy from Supplier
v 9302  (Selleck Chemicals)
93
Selleck Chemicals v 9302
V 9302, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v9302/V-9302/pmc08486573-90-6-16
Average 93 stars, based on 1 article reviews
v 9302 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
v9302 hydrochloride  (MedChemExpress)
93
MedChemExpress v9302 hydrochloride
Fig. 1 Schematic diagram illustrating antitumor effects by combining of UTMD and <t>FH-V9302-siGLUL-NDs</t> to cancer cells and CAFs
V9302 Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v9302/V-9302+hydrochloride/pm37420266-39-0-5
Average 93 stars, based on 1 article reviews
v9302 hydrochloride - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
fh-v9302-sifam-nds-dil  (Sifam Pharmaceuticals)
90
Sifam Pharmaceuticals fh-v9302-sifam-nds-dil
Fig. 1 Schematic diagram illustrating antitumor effects by combining of UTMD and <t>FH-V9302-siGLUL-NDs</t> to cancer cells and CAFs
Fh V9302 Sifam Nds Dil, supplied by Sifam Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v9302/fh+v9302+sifam+nds+dil/pmc10329298-133-9-22
Average 90 stars, based on 1 article reviews
fh-v9302-sifam-nds-dil - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
v9302  (Topscience Co Ltd)
90
Topscience Co Ltd v9302
Fig. 1 Schematic diagram illustrating antitumor effects by combining of UTMD and <t>FH-V9302-siGLUL-NDs</t> to cancer cells and CAFs
V9302, supplied by Topscience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/v9302/v9302/pm40258477-29-0-4
Average 90 stars, based on 1 article reviews
v9302 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
v-9302  (Aladdin Scientific Corporation)
N/A
description：V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 µM) in HEK-293 cells
   Buy from Supplier
v 9302  (Cayman Chemical)
N/A
V 9302
   Buy from Supplier
v-9302  (MuseChem Chemicals)
N/A
V-9302(CAT: I019215) is a potent, selective, and competitive antagonist of transmembrane glutamine flux that specifically targets the amino acid transporter ASCT2 (SLC1A5) without affecting ASCT1. It inhibits ASCT2-mediated glutamine uptake with an IC₅₀ of 9.6
   Buy from Supplier
v-9302  (Biosynth Carbosynth)
N/A
   Buy from Supplier
v-9302 hydrochloride  (TargetMol)
N/A
   Buy from Supplier
v-9302  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


Fig. 1 Schematic diagram illustrating antitumor effects by combining of UTMD and FH-V9302-siGLUL-NDs to cancer cells and CAFs

Journal: Journal of nanobiotechnology

Article Title: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.

doi: 10.1186/s12951-023-01979-z

Figure Lengend Snippet: Fig. 1 Schematic diagram illustrating antitumor effects by combining of UTMD and FH-V9302-siGLUL-NDs to cancer cells and CAFs

Article Snippet: V9302 hydrochloride was purchased from MedChemExpress (USA).

Techniques:

Fig. 2 Preparation and characterization of the nanodroplets. (A) Preparation of the nanodroplets. (B) Fluorescence microscope diagram of FH-V9302- siGLUL-NDs. Scale bars: 10 μm. (C) Transmission electron microscopy (TEM) of FH-V9302-siGLUL-NDs at a volume ratio of 1:20 ratio (siGLUL: nanodrop lets). Scale bars: 200 nm. (D) FH-V9302-siGLUL-NDs size distribution. (E) Drug release of FH-V9302-siGLUL-NDs with or without ultrasound stimulation (0.5 W/cm2, 60 s, 1.0 MHz). (F) US imaging in vitro. (G) US imaging in vivo. The red circle indicates the site of the tumor. All statistical data are expressed as means ± SD (n = 3)

Journal: Journal of nanobiotechnology

Article Title: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.

doi: 10.1186/s12951-023-01979-z

Figure Lengend Snippet: Fig. 2 Preparation and characterization of the nanodroplets. (A) Preparation of the nanodroplets. (B) Fluorescence microscope diagram of FH-V9302- siGLUL-NDs. Scale bars: 10 μm. (C) Transmission electron microscopy (TEM) of FH-V9302-siGLUL-NDs at a volume ratio of 1:20 ratio (siGLUL: nanodrop lets). Scale bars: 200 nm. (D) FH-V9302-siGLUL-NDs size distribution. (E) Drug release of FH-V9302-siGLUL-NDs with or without ultrasound stimulation (0.5 W/cm2, 60 s, 1.0 MHz). (F) US imaging in vitro. (G) US imaging in vivo. The red circle indicates the site of the tumor. All statistical data are expressed as means ± SD (n = 3)

Article Snippet: V9302 hydrochloride was purchased from MedChemExpress (USA).

Techniques: Fluorescence, Microscopy, Transmission Assay, Electron Microscopy, Imaging, In Vitro, In Vivo

Fig. 3 Characterization of FH-V9302-siGLUL-NDs and gene silencing efficiency. (A) Agarose gel electrophoresis retardation assay of FH-V9302-NDs with siGLUL in different volume ratios. (B) ζ potential changes of siGLUL with FH-V9302-NDs at different volume ratios (n = 3). (C) ζ potential of FH-V9302-NDs and FH-V9302-siGLUL-NDs (n = 3). (D) Western blot analysis of B16F10 and CAFs cells with different treatment knockdown GLUL levels. (E) Western blot analysis of different nanodroplets loading siGLUL knockdown GLUL levels. (F&G) Quantitative analysis of GLUL expression in B16F10(F) and CAFs(G) cells under different treatments. (H&I) Quantitative analysis of GLUL expression in B16F10 (H) and CAFs (I) cells treated with different nanodroplets loading siGLUL. *p < 0.05, **p < 0.01, ****p < 0.0001 (ANOVA test). All statistical data are expressed as means ± SD (n = 3)

Journal: Journal of nanobiotechnology

Article Title: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.

doi: 10.1186/s12951-023-01979-z

Figure Lengend Snippet: Fig. 3 Characterization of FH-V9302-siGLUL-NDs and gene silencing efficiency. (A) Agarose gel electrophoresis retardation assay of FH-V9302-NDs with siGLUL in different volume ratios. (B) ζ potential changes of siGLUL with FH-V9302-NDs at different volume ratios (n = 3). (C) ζ potential of FH-V9302-NDs and FH-V9302-siGLUL-NDs (n = 3). (D) Western blot analysis of B16F10 and CAFs cells with different treatment knockdown GLUL levels. (E) Western blot analysis of different nanodroplets loading siGLUL knockdown GLUL levels. (F&G) Quantitative analysis of GLUL expression in B16F10(F) and CAFs(G) cells under different treatments. (H&I) Quantitative analysis of GLUL expression in B16F10 (H) and CAFs (I) cells treated with different nanodroplets loading siGLUL. *p < 0.05, **p < 0.01, ****p < 0.0001 (ANOVA test). All statistical data are expressed as means ± SD (n = 3)

Article Snippet: V9302 hydrochloride was purchased from MedChemExpress (USA).

Techniques: Agarose Gel Electrophoresis, Western Blot, Knockdown, Expressing

Fig. 5 Safety evaluation. (A) Hemolytic behavior of Free V9302. (B) Hemolytic behavior of FH-V9302-siGLUL-NDs. (C) Hemolytic behavior of FH-NDs. (D) Statistics of hemolysis of Free V9302. (E) Statistics of hemolysis of FH-V9302-siGLUL-NDs. (F) Statistics of hemolysis of FH-NDs. (G) Agarose gel electro phoresis retardation assay of serum stability of naked siGLUL (a) and FH-V9302-siGLUL-NDs (b) in 50% fetal bovine serum. (H) Cytotoxicity of FH-NDs at different concentration in CAFs. (I) Cytotoxicity of FH-NDs at different concentration in B16F10. (J) Body weight changes of mice between treatments (n = 5). (K) H&E staining of major organs after intravenous injection of FH-V9302-siGLUL-NDs. Scale bar: 100 μm. *p < 0.05 (ANOVA test). All statistical data are expressed as means ± SD (n = 3)

Journal: Journal of nanobiotechnology

Article Title: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.

doi: 10.1186/s12951-023-01979-z

Figure Lengend Snippet: Fig. 5 Safety evaluation. (A) Hemolytic behavior of Free V9302. (B) Hemolytic behavior of FH-V9302-siGLUL-NDs. (C) Hemolytic behavior of FH-NDs. (D) Statistics of hemolysis of Free V9302. (E) Statistics of hemolysis of FH-V9302-siGLUL-NDs. (F) Statistics of hemolysis of FH-NDs. (G) Agarose gel electro phoresis retardation assay of serum stability of naked siGLUL (a) and FH-V9302-siGLUL-NDs (b) in 50% fetal bovine serum. (H) Cytotoxicity of FH-NDs at different concentration in CAFs. (I) Cytotoxicity of FH-NDs at different concentration in B16F10. (J) Body weight changes of mice between treatments (n = 5). (K) H&E staining of major organs after intravenous injection of FH-V9302-siGLUL-NDs. Scale bar: 100 μm. *p < 0.05 (ANOVA test). All statistical data are expressed as means ± SD (n = 3)

Article Snippet: V9302 hydrochloride was purchased from MedChemExpress (USA).

Techniques: Agarose Gel Electrophoresis, Concentration Assay, Staining, Injection

Fig. 10 In vivo antitumor efficacy and reprogramming of TME. (A) Photographs of tumor formed by B16F10 and CAFs after four treatments. (B) Changes of tumor volume during the treatment (n = 5) **p < 0.001(t-test). (C) Weight of tumors formed by B16F10 and CAFs after four treatments (n = 5). (D) H&E staining. Scale bar: 200 μm. (E) Ki67 staining. Scale bar: 200 μm. (F) Tunel staining. Scale bar: 200 μm. (G) Masson trichrome staining. Scale bar: 200 μm. (H) IHC staining of α-SMA. Scale bar: 200 μm. (I) IHC staining of GLUL. Scale bar: 200 μm. (J) Ki67 index analysis (n = 3). (K) Quantitative analysis of Tunel positive cells (n = 3). (L) Analysis of positive area of Masson (n = 3). (M) Quantitative analysis of α-SMA (n = 3). (N) Analysis of positive area of GLUL (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 (ANOVA test). All statistical data are expressed as means ± SD (n = 5). G1, Control; G2, FH-siGLUL-NDs; G3, FH-V9302- NDs; G4, Free V9302; G5, FH-V9302-siGLUL-NDs; G6, V9302-siGLUL-NDs + US; and G7, FH-V9302-siGLUL-NDs + US

Journal: Journal of nanobiotechnology

Article Title: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.

doi: 10.1186/s12951-023-01979-z

Figure Lengend Snippet: Fig. 10 In vivo antitumor efficacy and reprogramming of TME. (A) Photographs of tumor formed by B16F10 and CAFs after four treatments. (B) Changes of tumor volume during the treatment (n = 5) **p < 0.001(t-test). (C) Weight of tumors formed by B16F10 and CAFs after four treatments (n = 5). (D) H&E staining. Scale bar: 200 μm. (E) Ki67 staining. Scale bar: 200 μm. (F) Tunel staining. Scale bar: 200 μm. (G) Masson trichrome staining. Scale bar: 200 μm. (H) IHC staining of α-SMA. Scale bar: 200 μm. (I) IHC staining of GLUL. Scale bar: 200 μm. (J) Ki67 index analysis (n = 3). (K) Quantitative analysis of Tunel positive cells (n = 3). (L) Analysis of positive area of Masson (n = 3). (M) Quantitative analysis of α-SMA (n = 3). (N) Analysis of positive area of GLUL (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 (ANOVA test). All statistical data are expressed as means ± SD (n = 5). G1, Control; G2, FH-siGLUL-NDs; G3, FH-V9302- NDs; G4, Free V9302; G5, FH-V9302-siGLUL-NDs; G6, V9302-siGLUL-NDs + US; and G7, FH-V9302-siGLUL-NDs + US

Article Snippet: V9302 hydrochloride was purchased from MedChemExpress (USA).

Techniques: In Vivo, Staining, TUNEL Assay, Immunohistochemistry, Control